molecular trial run continue to grow rapidly, increasing by around 30%.
given that June and reaching a peak of about 775,000 day-to-day tests administered by.
mid-July. High-quality serology screening, licensed by FDA, is now offered at.
scale with industry capability to produce 100 million tests monthly.
” This incredible turning point is just the current example of how the medical innovation industry is increasing to fulfill the obstacles postured by the COVID-19 pandemic,” stated Scott Whitaker, AdvaMed president and CEO. “Widespread and widely offered testing is key to our capability as a country to conquer this public health crisis, and our industry is dedicated to providing the screening supplies and details healthcare companies need in order to accomplish the necessary testing capacity.”
The Advanced Medical Innovation Association (AdvaMed) today announced that deliveries of COVID-19 molecular diagnostic tests reached one million per day for the week ending July 24, based upon the current information from the associations National Screening Registry.
AdvaMed and AdvaMedDx, the associations department of diagnostics companies, established the National Testing Registry in partnership with 13 commercial diagnostics makers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific..
July 21, AdvaMeds Registry assembles details from diagnostic business.
in addition to publicly offered data on daily tests carried out to create a.
centralized and standardized COVID-19 diagnostic supply windows registry. The pc registry.
will provide weekly state- and national-level updates on the variety of.
molecular, antigen, and serology (antibody) tests delivered in the U.S. to.
assistance state and federal governments in their pandemic responses.